血必净注射液辅助治疗慢性阻塞性肺疾病急性加重的疗效与安全性及免疫调节影响:随机对照试验研究方案
本研究为前瞻性、随机、安慰剂对照、盲法、多中心试验,计划纳入300例AECOPD患者,按1:1随机接受常规治疗联合血必净注射液或0.9%氯化钠注射液,治疗5天,主要结局为第28天气管插管率,并评估免疫炎症指标、呼吸支持、死亡率等。
要点
- 血必净注射液辅助治疗AECOPD的多中心随机对照试验,样本量300例。
- 主要结局为第28天气管插管率,次要结局包括免疫炎症指标和28天死亡率。
- 治疗组在常规用药基础上加用血必净注射液,对照组加用0.9%氯化钠注射液,疗程5天。
核心结论
- 该试验旨在评估血必净注射液作为AECOPD辅助治疗的疗效与安全性,并基于T细胞水平变化探索其对免疫功能的影响。
研究设计与样本
- 前瞻性、随机、安慰剂对照、盲法、多中心试验,计划纳入300例合格AECOPD患者,按1:1比例通过中央随机化系统分配至治疗组或安慰剂对照组。
主要发现
- 治疗组接受常规药物加血必净注射液,对照组接受常规药物加0.9%氯化钠注射液,入组24小时内开始相应治疗,持续5天。
- 主要结局为治疗后第28天气管插管率,次要结局包括免疫和炎症指标变化、呼吸支持、28天死亡率、血气分析、APACHE II评分和临床症状改善、ICU及住院时间和费用。
关键数值与推荐
- 主要结局指标为第28天气管插管率。
- 次要结局包括免疫和炎症指标变化、呼吸支持、28天死亡率、血气分析、APACHE II评分改善、临床症状改善、ICU住院时间和费用及总住院时间和费用。
- 安全性在整个试验期间评估。
临床怎么用
- 该试验结果将为AECOPD管理中血必净注射液辅助治疗的推荐提供临床证据,并有助于识别其潜在机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is the leading cause of mortality in chronic obstructive pulmonary disease (COPD). Traditional Chinese medicine (TCM) has been widely used in Asia as an adjunct treatment for AECOPD to improve the patients' symptoms. Xuebijing (XBJ) injection is one of the major herbal medicines used in TCM. Previous small-sample clinical trials have proven its efficacy and safety in the treatment of AECOPD; however, the current data on XBJ as an adjunct therapy are insufficient. The present study will be a multi-center randomized clinical trial (RCT) to evaluate the efficacy and safety of XBJ injection in AECOPD and explore its influence on the immune function based on the altered levels of T cells. METHODS: This study will be a prospective, randomized, placebo-controlled, blinded, multi-center trial. A total of 300 eligible patients will be randomly assigned to the treatment or placebo control group in a 1:1 ratio using a central randomization system. The treatment group will receive routine medication plus XBJ injection, and the control group will receive routine medication plus 0.9% NaCl injection. The patients will receive the corresponding treatment for 5 days starting within 24 h of enrollment. The primary outcome, the of rate endotracheal intubation, will be evaluated on day 28 after treatment. The secondary outcomes will include changes in immune and inflammatory indicators, respiratory support, mortality rate after 28 days, blood gas analysis, improvement in Acute physiology and chronic health evaluation (APACHE) II scores and clinical symptoms, and the length and cost of intensive care unit stay and hospitalization. The safety of the interventions will be assessed throughout the trial. DISCUSSION: This is the first and largest randomized, controlled, blinded trial that evaluates the efficacy of XBJ injection as adjuvant therapy for AECOPD. The results of this trial will provide valuable clinical evidence for recommendations on the management of the disease and identify the underlying mechanisms. TRIAL REGISTRATION: ClinicalTrials.gov, NCT02937974 . Registered on 13 October 2016. Chinese clinical trial registry, ChiCTR-IPR-17011667. Registered on 15 June 2017.
引用
- Xie S, Yan P, Yao C, et al. Efficacy and safety of Xuebijing injection and its influence on immunomodulation in acute exacerbations of chronic obstructive pulmonary disease: study protocol for a randomized controlled trial. Trials. 2019. PMID: 30777117. doi:10.1186/s13063-019-3204-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。